SOD1

SOD1

SOD1 Informations sur la molécule

Molecule Name
Superoxide dismutase
Alias de la molécule
SOD1,Superoxide dismutase 1,hSod1
Drug Development Progress
Nombre de médicaments cliniques13
Nombre de médicaments commercialisés3
Phase de R&D la plus avancéeApproved
Alias de la cible
SOD1,Superoxide Dismutase 1,HSod1,Amyotrophic Lateral Sclerosis 1 (Adult),Epididymis Secretory Protein Li 44,Superoxide Dismutase [Cu-Zn],Cu/Zn Superoxide Dismutase,Indophenoloxidase A,SOD, Soluble,EC 1.15.1.1,HEL-S-44,IPOA,ALS1,SOD,ALS,Superoxide Dismutase,STAHP,EC:1.15.1.1,Superoxide Dismutase 1, Soluble,Superoxide Dismutase, Cystolic,Homodimer
Contexte de la molécule
Superoxide dismutase [Cu-Zn] (SOD1) is also known as superoxide dismutase 1 (hSod1), an enzyme that in humans is encoded by the SOD1 gene, located on chromosome 21. SOD1 can bind copper and zinc ions and is one of three superoxide dismutases responsible for destroying free superoxide radicals in the body. The encoded isozyme (SOD1) is a soluble cytoplasmic and mitochondrial intermembrane space protein, acting as a homodimer to convert naturally occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide. Furthermore, the mutations of SOD1 gene can result in a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord.

SOD1 Liste de produits

Species
  • Human(2)
Tag
  • His Tag(2)
Host
  • E. coli(2)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • Yes(1)
  • No(1)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
SOD1
Human SOD1 / Cu-Zn SOD Pre-formed Fibrils Protein, His Tag
Human
E. coli

$400.00

100ug
SOD1
Human SOD1 / Cu-Zn SOD Protein, His Tag, low Endotoxin (active enzyme)
Human
E. coli
SDS-PAGE
Enzyme

$205.00

100ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
OtaplimastatSP-8203 hydrochloride; SP8203 HCL; SP-8203Phase 3 ClinicalShin Poong Pharmaceutical Co Ltd
Ischemic Stroke
Details
Bis-choline tetrathiomolybdateATN-224; WTX-101; ALXN-1840Phase 2 ClinicalWilson Therapeutics
Hepatolenticular Degeneration; Melanoma; Multiple Myeloma; Prostatic Neoplasms
Details
Superoxide dismutase (Ube Industries)r-hSOD; FKU-871Phase 2 ClinicalAstellas Pharma Inc, Ube Industries Ltd
Diabetic Neuropathies; Myocardial Ischemia
Details
BMX-010BMX-010; MnTE-2-PyP; MnTE-2-PyP5+Phase 2 ClinicalDuke University
Acne Vulgaris; Dermatitis, Atopic; Psoriasis; Rosacea
Details
TempolMBM-02; OT-674; NSC-142784; MTS-02; MTS-10; MTS-01; APC-410; APC-400; REC-994; MBM-01; REC-0000994Phase 2 ClinicalMitos
Alopecia; Anus Neoplasms; Ataxia Telangiectasia; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Hemangioma, Cavernous, Central Nervous System; Mucositis; Ototoxicity; Prostatic Neoplasms
Details
Superoxide dismutase analogue (LTT Bio-Pharma)LT-1001; LT-0011; PC-SOD NE; PC-SOD; LT-1002Phase 2 ClinicalLTT Bio-Pharma Co Ltd
Colitis, Ulcerative; Idiopathic Pulmonary Fibrosis; Myocardial Infarction; Peripheral Nervous System Diseases; Respiratory Distress Syndrome, Adult; Stroke
Details
RAG-17RAG-17; RD-12500Phase 2 ClinicalRactigen Therapeutics (Nantong) Co Ltd
Amyotrophic Lateral Sclerosis
Details
ALN-SODALN-SODPhase 2 ClinicalAlnylam Pharmaceuticals Inc
Amyotrophic Lateral Sclerosis
Details
NI-005AP-101 (AL-S Pharma); NI-005Phase 2 ClinicalAl-S Pharma Ag
Amyotrophic Lateral Sclerosis
Details
APB-102APB-102; AMT-162Phase 2 ClinicalUniversity Of Massachusetts Medical School
Amyotrophic Lateral Sclerosis
Details
NAS150AEOL-10150; NAS150; NAS-150Phase 1 ClinicalAeolus Pharmaceuticals
Idiopathic Pulmonary Fibrosis; Lung Injury; Neoplasms; Supranuclear Palsy, Progressive
Details
INS-1202INS1202; INS-1202Phase 1 ClinicalInsmed
Amyotrophic Lateral Sclerosis
Details
[89Zr]Zr-DFO-AP-101Phase 1 ClinicalUniversité De Sherbrooke
Amyotrophic Lateral Sclerosis; Tooth Diseases
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
OrgoteinApprovedGt Biopharma IncOntoseinSpainRheumatic Diseases; Cystitis; Radiation Injuriesnull1996-01-01
Cystitis; Radiation Injuries; Rheumatic Diseases
Details
Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc SulfateApprovedAmerican Regent IncMULTRYSUnited StatesDietary SupplementAmerican Regent Inc2020-07-02
Dietary Supplement
Details
Tofersen99mTc-MAG3-BIIB067; ISIS-333611; BIIB-067; SODr/h333611; ISIS-SOD1Rx; IONIS SOD1RxApprovedIonis Pharmaceuticals Inc, Ludwig Institute For Cancer ResearchQALSODY, Qalsody, 凯盛迪United StatesAmyotrophic Lateral SclerosisBiogen Ma Inc, Biogen Inc2023-04-25
Amyotrophic Lateral Sclerosis; Familial Amyotrophic Lateral Sclerosis
Details
Customer Reviews